<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563834</url>
  </required_header>
  <id_info>
    <org_study_id>10100002643</org_study_id>
    <secondary_id>R21DK071142</secondary_id>
    <nct_id>NCT02563834</nct_id>
  </id_info>
  <brief_title>A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism</brief_title>
  <official_title>A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies of myocardial fuel selection using a novel palmitate-based PET probe
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A novel Positron Emission Tomography (PET) probe, 16- 18-F-fluoro-4-thiapalmitate, will be
      used to evaluate myocardial atty acid uptake. Studies will be done in humans with type 2
      diabetes mellitus, and in controls. Studies will take place on 2 separate days, under fasting
      conditions and under insulin clamp conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Fatty Acid Uptake Rate</measure>
    <time_frame>4 Hours</time_frame>
    <description>PET measure of fatty acid uptake rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Oxidation Rate</measure>
    <time_frame>4 Hours</time_frame>
    <description>PET measure of total oxidation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Perfusion Rate</measure>
    <time_frame>4 Hours</time_frame>
    <description>PET measure of total myocardial perfusion (blood flow)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Clamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiapalmitate tracer</intervention_name>
    <description>Radiolabeled tracer infusion; occurs in all treatment arms</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Insulin Clamp</arm_group_label>
    <other_name>16- 18-F-fluoro-4-thiapalmitate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion for control</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin infusion for insulin/glucose clamp procedure</description>
    <arm_group_label>Insulin Clamp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lean:

               -  BMI&lt;25 kg/m2

               -  normal glucose tolerance by 75g oral glucose tolerance test

          -  Type 2 diabetes mellitus:

               -  BMI &gt;25 kg/m2

               -  previously diagnosed type 2 diabetes mellitus

               -  on oral and/or injected insulin treatment.

        Exclusion Criteria:

          -  Lean:

             *Use of any chronic medications

          -  Type 2 diabetes mellitus

               -  known microvascular disease

               -  known coronary or other macro vascular disease

               -  use of PPARgamma class antidiabetic agents within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kieren J Mather, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital GCRC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mather KJ, Hutchins GD, Perry K, Territo W, Chisholm R, Acton A, Glick-Wilson B, Considine RV, Moberly S, DeGrado TR. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. Am J Physiol Endocrinol Metab. 2016 Mar 15;310(6):E452-60. doi: 10.1152/ajpendo.00437.2015. Epub 2016 Jan 5.</citation>
    <PMID>26732686</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <results_first_submitted>February 29, 2016</results_first_submitted>
  <results_first_submitted_qc>August 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2016</results_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lean Control</title>
          <description>Studies will be performed on 2 separate days under fasting conditions, using a saline infusion on Day 1 and insulin infusion on Day 2. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate) on both study days.
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Saline: Saline infusion for control</description>
        </group>
        <group group_id="P2">
          <title>Type 2 DM</title>
          <description>Studies will be performed on 2 separate days under fasting conditions, using a saline infusion on Day 1 and insulin infusion on Day 2. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate) on both study days.
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Control (Saline) Infusion (*Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Insulin Infusion (*Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lean Controls</title>
          <description>Lean non-diabetic control participants, taking no regular medications.</description>
        </group>
        <group group_id="B2">
          <title>Type 2 Diabetes</title>
          <description>Participants with Type 2 diabetes treated with any combination of oral agents and insulin except PPARgamma agonists.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="9.0"/>
                    <measurement group_id="B2" value="40.4" spread="9.2"/>
                    <measurement group_id="B3" value="36.9" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Fatty Acid Uptake Rate</title>
        <description>PET measure of fatty acid uptake rate</description>
        <time_frame>4 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Control - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Saline: Saline infusion for control</description>
          </group>
          <group group_id="O2">
            <title>Lean Control - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Insulin: Insulin infusion for insulin/glucose clamp procedure</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
          <group group_id="O4">
            <title>Type 2 DM - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Fatty Acid Uptake Rate</title>
          <description>PET measure of fatty acid uptake rate</description>
          <units>umol/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.492" spread="3.942"/>
                    <measurement group_id="O2" value="2.123" spread="1.087"/>
                    <measurement group_id="O3" value="36.005" spread="4.408"/>
                    <measurement group_id="O4" value="7.8" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Oxidation Rate</title>
        <description>PET measure of total oxidation rate</description>
        <time_frame>4 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Control - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Saline: Saline infusion for control</description>
          </group>
          <group group_id="O2">
            <title>Lean Control - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Insulin: Insulin infusion for insulin/glucose clamp procedure</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
          <group group_id="O4">
            <title>Type 2 DM - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Oxidation Rate</title>
          <description>PET measure of total oxidation rate</description>
          <units>ml/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.006" spread="0.951"/>
                    <measurement group_id="O2" value="19.847" spread="1.773"/>
                    <measurement group_id="O3" value="17.381" spread="1.064"/>
                    <measurement group_id="O4" value="22.940" spread="2.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Perfusion Rate</title>
        <description>PET measure of total myocardial perfusion (blood flow)</description>
        <time_frame>4 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Control - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Saline: Saline infusion for control</description>
          </group>
          <group group_id="O2">
            <title>Lean Control - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Insulin: Insulin infusion for insulin/glucose clamp procedure</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM - Saline</title>
            <description>Studies will be performed on a separate day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
          <group group_id="O4">
            <title>Type 2 DM - Insulin Clamp</title>
            <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Perfusion Rate</title>
          <description>PET measure of total myocardial perfusion (blood flow)</description>
          <units>ml/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="2.1"/>
                    <measurement group_id="O2" value="46.5" spread="3.3"/>
                    <measurement group_id="O3" value="44.2" spread="2.3"/>
                    <measurement group_id="O4" value="49.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Saline: Saline infusion for control</description>
        </group>
        <group group_id="E2">
          <title>Insulin Clamp</title>
          <description>Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
thiapalmitate tracer: Radiolabeled tracer infusion; occurs in all treatment arms
Insulin: Insulin infusion for insulin/glucose clamp procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kieren J Mather</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-7826</phone>
      <email>kmather@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

